SEP 09, 2020 12:47 PM PDT

New Achondroplasia Treatment

WRITTEN BY: Nouran Amin

A recent clinical trial study found that an experimental drug, known as vosoritide, can be a potential treatment for achondroplasia (a common type of child dwarfism).

"This drug is like releasing the handbrake on a car, it lets you get up to full speed instead of having to drive with the brakes on,” says MCRI clinical geneticist Professor Ravi Savarirayan.

Achondroplasia results in the over activity of a protein FGFR3 that negatively impacts bone growth. Currently treatments involve surgical interventions in comparison—vosoritide can me potentially be a molecular therapy targeting the origins of the disease without invasiveness.

Professor Savarirayan said, "We know that beyond the cold hard facts and figures around growth rates and bone biology, we have hope that a treatment can improve kids' health outcomes, social functioning and increase access to their environments. Anecdotally, our patients tell us they now are able to do more stuff like climbing trees, jumping rocks and being more independent generally, which is specific to their experiences."

Learn more about Achondroplasia:

https://www.youtube.com/watch?v=gt-SAjuikLM

Findings were published in the medical journal, The Lancet and describes how Vosoritide works by blocking FGFR3 activity and returning bone growth to normal.

Dr. Johnathon Day, the Medical Director of Clinical Science at BioMarin Pharmaceutical Inc. notes, "Vosoritide is the first potential precision pharmacological therapy that addresses the underlying cause of achondroplasia and this randomized, double-blind, placebo-controlled Phase 3 study further adds to the scientific knowledge we've gained over many years from the clinical development program. I'd like to personally thank and congratulate all of the investigators and I am especially grateful to all of the children and their families who have participated in these studies.”

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUN 14, 2022
Cancer
Maintaining Sample Temperature: Q&A From a Corning Scientist
JUN 14, 2022
Maintaining Sample Temperature: Q&A From a Corning Scientist
Generally speaking, bad things can happen when a cell sample temperature gets too hot or too cold. Temperature instabili ...
JUN 02, 2022
Coronavirus
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
JUN 02, 2022
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
It has been clear for some time that loneliness and social isolation can lead to increased risks for adverse h ...
JUN 13, 2022
Microbiology
Mucus Contains Fungus-Fighting Molecules
JUN 13, 2022
Mucus Contains Fungus-Fighting Molecules
The human body plays host to a variety of microorganisms, including fungi like Candida albicans. Some strains of Candida ...
JUN 15, 2022
Plants & Animals
Using Mosquito Spit to Develop Vaccines for Zika, Yellow Fever, Dengue
JUN 15, 2022
Using Mosquito Spit to Develop Vaccines for Zika, Yellow Fever, Dengue
Mosquitoes, specifically, the Aedes mosquito, can carry and transmit deadly virsues like the Zika virus and the viruses ...
JUL 15, 2022
Immunology
Pox Virus Proteins Can Launch Early Attack on Immune Defense
JUL 15, 2022
Pox Virus Proteins Can Launch Early Attack on Immune Defense
After a virus gets inside of a cell, it typically takes over the cell to produce more viral particles. But pox viruses g ...
JUL 23, 2022
Drug Discovery & Development
Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19
JUL 23, 2022
Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19
An anti-inflammatory compound has shown promise in treating systemic inflammation and brain injury in patients with seve ...
Loading Comments...